IASLC and ESMO Present 6th European Lung Cancer Conference

Novel RET Inhibitors Promising in Chinese Patients with RET-fusion Positive NSCLC

Second-Line Platinum-Doublet Regimens Reasonable in SCLC

Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations

Keynote Addresses Lessons from SCLC Mouse Models

CDX Models Help Bring Personalized Treatment for SCLC a Step Closer

Preconditioning Program Shortens Postsurgical Hospital Stay for People with Lung Cancer

In Brief for February 9, 2022

Regulatory News for February 9, 2022

In Brief for February 23, 2022

Regulatory News for February 23, 2022

The FDA Explained: An Interview with Dr. Harpreet Singh